Citadel Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$224M Sell
1,030,200
-402,600
-28% -$89.3M 0.04% 407
2025
Q4
$327M Sell
1,432,800
-456,400
-24% -$104M 0.05% 308
2025
Q3
$437M Buy
1,889,200
+648,300
+52% +$132M 0.07% 224
2025
Q2
$230M Sell
1,240,900
-1,107,000
-47% -$206M 0.04% 363
2025
Q1
$492M Buy
2,347,900
+937,100
+66% +$182M 0.09% 132
2024
Q4
$251M Sell
1,410,800
-457,300
-24% -$84.1M 0.04% 318
2024
Q3
$369M Buy
1,868,100
+1,088,300
+140% +$203M 0.07% 197
2024
Q2
$134M Sell
779,800
-753,000
-49% -$125M 0.03% 522
2024
Q1
$279M Buy
1,532,800
+397,800
+35% +$68.6M 0.05% 259
2023
Q4
$176M Sell
1,135,000
-341,800
-23% -$49.8M 0.04% 401
2023
Q3
$220M Sell
1,476,800
-624,100
-30% -$91.6M 0.05% 286
2023
Q2
$283M Sell
2,100,900
-123,700
-6% -$18.1M 0.06% 191
2023
Q1
$355M Sell
2,224,600
-265,700
-11% -$40.6M 0.08% 159
2022
Q4
$402M Buy
2,490,300
+313,000
+14% +$48M 0.09% 147
2022
Q3
$292M Sell
2,177,300
-335,100
-13% -$48.1M 0.07% 190
2022
Q2
$385M Sell
2,512,400
-469,100
-16% -$71.7M 0.1% 124
2022
Q1
$483M Buy
2,981,500
+1,316,514
+79% +$191M 0.1% 110
2021
Q4
$225M Sell
1,664,986
-617,000
-27% -$72.9M 0.05% 301
2021
Q3
$246M Buy
2,281,986
+329,500
+17% +$37.7M 0.05% 277
2021
Q2
$220M Buy
1,952,486
+210,100
+12% +$23.7M 0.05% 288
2021
Q1
$189M Buy
1,742,386
+206,138
+13% +$22M 0.05% 312
2020
Q4
$165M Sell
1,536,248
-252,752
-14% -$24.3M 0.04% 330
2020
Q3
$157M Sell
1,789,000
-157,800
-8% -$14.9M 0.04% 273
2020
Q2
$191M Buy
1,946,800
+72,200
+4% +$6.36M 0.07% 194
2020
Q1
$143M Sell
1,874,600
-2,249,800
-55% -$192M 0.06% 219
2019
Q4
$365M Buy
4,124,400
+630,600
+18% +$52.4M 0.16% 71
2019
Q3
$265M Buy
3,493,800
+472,500
+16% +$32.4M 0.12% 105
2019
Q2
$220M Buy
3,021,300
+1,143,900
+61% +$89.9M 0.1% 141
2019
Q1
$151M Buy
1,877,400
+571,500
+44% +$46.8M 0.08% 219
2018
Q4
$120M Sell
1,305,900
-10,700
-0.8% -$941K 0.07% 267
2018
Q3
$125M Buy
1,316,600
+255,800
+24% +$24.3M 0.06% 333
2018
Q2
$98.3M Buy
1,060,800
+184,100
+21% +$18M 0.05% 376
2018
Q1
$83M Buy
876,700
+155,200
+22% +$17M 0.05% 390
2017
Q4
$69.8M Buy
721,500
+100,300
+16% +$9.45M 0.04% 466
2017
Q3
$55.2M Buy
621,200
+126,900
+26% +$9.66M 0.04% 497
2017
Q2
$35.8M Buy
494,300
+49,800
+11% +$3.35M 0.03% 661
2017
Q1
$29M Sell
444,500
-105,000
-19% -$6.6M 0.03% 739
2016
Q4
$34.4M Buy
549,500
+75,900
+16% +$4.63M 0.03% 553
2016
Q3
$29.9M Buy
473,600
+106,400
+29% +$6.89M 0.03% 640
2016
Q2
$22.7M Buy
367,200
+33,400
+10% +$2.04M 0.03% 693
2016
Q1
$19.1M Buy
333,800
+74,200
+29% +$4.14M 0.02% 774
2015
Q4
$15.4M Sell
259,600
-48,000
-16% -$2.76M 0.02% 997
2015
Q3
$16.7M Buy
307,600
+66,000
+27% +$4.3M 0.02% 1005
2015
Q2
$16.2M Buy
241,600
+26,600
+12% +$1.74M 0.01% 1144
2015
Q1
$12.6M Sell
215,000
-48,200
-18% -$2.91M 0.01% 1270
2014
Q4
$17.2M Buy
263,200
+147,000
+127% +$9.27M 0.02% 1046
2014
Q3
$6.71M Sell
116,200
-54,500
-32% -$3.03M 0.01% 1716
2014
Q2
$9.63M Buy
170,700
+72,900
+75% +$3.82M 0.01% 1293
2014
Q1
$5.03M Sell
97,800
-73,300
-43% -$3.7M 0.01% 1782
2013
Q4
$9.04M Buy
171,100
+28,400
+20% +$1.4M 0.01% 1268
2013
Q3
$6.38M Buy
142,700
+46,800
+49% +$2.07M 0.01% 1398
2013
Q2
$3.96M Buy
+95,900
New +$4.19M 0.01% 1784

Other funds holding ABBV

Citadel Advisors's ABBV Position: Q1 2026 in Review

Citadel Advisors reduced its AbbVie (ABBV) stake by 33% in Q1 2026, selling an estimated $53.9M and leaving 490,285 shares worth $107M. The position accounts for 0.02% of the portfolio, ranked #768.

Citadel Advisors first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $719M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Citadel Advisors held 490,285 shares of AbbVie worth $107M as of Q1 2026.
  • Citadel Advisors sold 243,066 AbbVie shares in Q1 2026, an estimated $53.9M.
  • AbbVie made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #768 holding.
  • Citadel Advisors first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's AbbVie position peaked at $719M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.